Articles producció científica> Medicina i Cirurgia

Arterial Stiffness in Type 1 Diabetes: The Case for the Arterial Wall Itself as a Target Organ

  • Identification data

    Identifier: imarina:9226641
    Authors:
    Gonzalez-Clemente, Jose-MiguelCano, AlbertAlbert, LaraGimenez-Palop, OlgaRomero, AnaBerlanga, EugenioVendrell, JoanLlaurado, Gemma
    Abstract:
    Arterial stiffness (AS) integrates the cumulative burden of known and unknown cardiovascular risk factors on the elastic wall of large arteries along the lifespan of an individual. As a marker of vascular aging, AS is an independent predictor of cardiovascular events and improves cardiovascular risk prediction when added to the Framingham Risk Score. In addition, AS may affect the microvasculature and promote the development of microvascular complications. Its impact on both the macro- and microvasculature has led to the concept that the arterial wall itself should be considered as a target organ. Here, we review the biological and clinical consequences of AS on the macro- and microvasculature and the measurement of AS in routine clinical practice. We also discuss the pathophysiological mechanisms underpinning AS development using diabetes and, in particular, type 1 diabetes, as a disease model with a high risk of cardiovascular events and microvascular complications that are accelerated by AS.
  • Others:

    Author, as appears in the article.: Gonzalez-Clemente, Jose-Miguel; Cano, Albert; Albert, Lara; Gimenez-Palop, Olga; Romero, Ana; Berlanga, Eugenio; Vendrell, Joan; Llaurado, Gemma;
    Department: Medicina i Cirurgia
    URV's Author/s: Vendrell Ortega, Juan José
    Keywords: Very low density lipoprotein Untranslated rna Type 1 diabetes Triacylglycerol Treatment outcome Tonometry Target organ Risk-factors Review Renin angiotensin aldosterone system Recommendations Pulse wave velocity Pulse wave Prospective study Prediction Peripheral neuropathy Pathophysiology Parathyroid hormone Oscillometry Nuclear magnetic resonance imaging Non invasive measurement Nitric oxide Microvasculature Microvascular complications Microrna Mechanisms Measurement Low density lipoprotein Liraglutide Lipoprotein particles Lipoprotein Insulin resistance Insulin dependent diabetes mellitus Inflammation Hypertension Hyperglycemia Hypercholesterolemia Hydroxymethylglutaryl coenzyme a reductase inhibitor Human High density lipoprotein Ezetimibe Expert consensus document Evolocumab Endothelial dysfunction Empagliflozin Elastin Elasticity Echocardiography Drug effect Double diabetes Diuretic agent Diabetic retinopathy Diabetic neuropathy Diabetic nephropathy Diabetic microangiopathy Diabetic complication Diabetes mellitus Cross-sectional study Collagen Clinical practice Cholesterol Cardiovascular-disease Cardiovascular risk Cardiovascular disease Cardiac autonomic neuropathy Calcium channel blocking agent Blood pressure Biological marker Beta adrenergic receptor blocking agent Atherosclerotic plaque Atherosclerosis Association Artery calcification Arterial stiffness Apolipoprotein a5 Aortic stiffness Aorta Antihypertensive therapy Alirocumab Albuminuria Aging Adult Adiponectin
    Abstract: Arterial stiffness (AS) integrates the cumulative burden of known and unknown cardiovascular risk factors on the elastic wall of large arteries along the lifespan of an individual. As a marker of vascular aging, AS is an independent predictor of cardiovascular events and improves cardiovascular risk prediction when added to the Framingham Risk Score. In addition, AS may affect the microvasculature and promote the development of microvascular complications. Its impact on both the macro- and microvasculature has led to the concept that the arterial wall itself should be considered as a target organ. Here, we review the biological and clinical consequences of AS on the macro- and microvasculature and the measurement of AS in routine clinical practice. We also discuss the pathophysiological mechanisms underpinning AS development using diabetes and, in particular, type 1 diabetes, as a disease model with a high risk of cardiovascular events and microvascular complications that are accelerated by AS.
    Thematic Areas: Medicine, general & internal Medicine (miscellaneous) Medicine (all)
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: juanjose.vendrell@urv.cat
    Author identifier: 0000-0002-6994-6115
    Record's date: 2024-07-27
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.mdpi.com/2077-0383/10/16/3616
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Journal Of Clinical Medicine. 10 (16):
    APA: Gonzalez-Clemente, Jose-Miguel; Cano, Albert; Albert, Lara; Gimenez-Palop, Olga; Romero, Ana; Berlanga, Eugenio; Vendrell, Joan; Llaurado, Gemma; (2021). Arterial Stiffness in Type 1 Diabetes: The Case for the Arterial Wall Itself as a Target Organ. Journal Of Clinical Medicine, 10(16), -. DOI: 10.3390/jcm10163616
    Article's DOI: 10.3390/jcm10163616
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2021
    Publication Type: Journal Publications
  • Keywords:

    Medicine (Miscellaneous),Medicine, General & Internal
    Very low density lipoprotein
    Untranslated rna
    Type 1 diabetes
    Triacylglycerol
    Treatment outcome
    Tonometry
    Target organ
    Risk-factors
    Review
    Renin angiotensin aldosterone system
    Recommendations
    Pulse wave velocity
    Pulse wave
    Prospective study
    Prediction
    Peripheral neuropathy
    Pathophysiology
    Parathyroid hormone
    Oscillometry
    Nuclear magnetic resonance imaging
    Non invasive measurement
    Nitric oxide
    Microvasculature
    Microvascular complications
    Microrna
    Mechanisms
    Measurement
    Low density lipoprotein
    Liraglutide
    Lipoprotein particles
    Lipoprotein
    Insulin resistance
    Insulin dependent diabetes mellitus
    Inflammation
    Hypertension
    Hyperglycemia
    Hypercholesterolemia
    Hydroxymethylglutaryl coenzyme a reductase inhibitor
    Human
    High density lipoprotein
    Ezetimibe
    Expert consensus document
    Evolocumab
    Endothelial dysfunction
    Empagliflozin
    Elastin
    Elasticity
    Echocardiography
    Drug effect
    Double diabetes
    Diuretic agent
    Diabetic retinopathy
    Diabetic neuropathy
    Diabetic nephropathy
    Diabetic microangiopathy
    Diabetic complication
    Diabetes mellitus
    Cross-sectional study
    Collagen
    Clinical practice
    Cholesterol
    Cardiovascular-disease
    Cardiovascular risk
    Cardiovascular disease
    Cardiac autonomic neuropathy
    Calcium channel blocking agent
    Blood pressure
    Biological marker
    Beta adrenergic receptor blocking agent
    Atherosclerotic plaque
    Atherosclerosis
    Association
    Artery calcification
    Arterial stiffness
    Apolipoprotein a5
    Aortic stiffness
    Aorta
    Antihypertensive therapy
    Alirocumab
    Albuminuria
    Aging
    Adult
    Adiponectin
    Medicine, general & internal
    Medicine (miscellaneous)
    Medicine (all)
  • Documents:

  • Cerca a google

    Search to google scholar